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Objectives We sought to evaluate the significance of high-density lipoprotein cholesterol (HDL-C) in the context of low low-
density lipoprotein cholesterol (LDL-C).
Background Earlier studies support an inverse correlation between circulating HDL-C and coronary risk in patients with nor-
mal or elevated LDL-C.
Methods This study involved 4,188 patients attending the Palo Alto Veterans Administration Medical Center or affiliated
clinics with LDL-C levels below 60 mg/dl. Outcomes were examined 1 year after the index LDL-C date. The com-
bined primary end point was myocardial injury or hospitalization from ischemic heart disease. The secondary
end point was all-cause mortality.
Results Mean HDL-C levels (mg/dl) by quartile (Q) were: Q1 28 mg/dl, Q2 36 mg/dl, Q3 43 mg/dl, and Q4 63 mg/dl.
The rate of myocardial injury or hospitalization for ischemic heart disease showed an inverse relationship to
HDL-C (adjusted odds ratios: Q1 1.59 [95% confidence interval (CI) 1.16 to 2.19], Q2 1.39 [95% CI 1.01 to
1.92], Q3 1.33 [95% CI 0.96 to 1.84], and Q4 reference) that persisted regardless of statin use or recent myo-
cardial injury. Analyzing HDL-C as a continuous variable revealed a 10% [95% CI 3% to 17%] increase in the
combined end point of myocardial injury or hospitalization for ischemic heart disease for every 10-mg/dl de-
crease in HDL-C. The unadjusted and adjusted incidence of all-cause mortality demonstrated a U-shaped rela-
tionship to HDL-C (adjusted odds ratios: Q1 1.13 [95% CI 0.79 to 1.62], Q2 0.97 [95% CI 0.67 to 1.40], Q3 0.74
[95% CI 0.50 to 1.09], and Q4 reference).
Conclusions The inverse relationship between HDL-C and coronary risk persists even among patients with LDL-C below 60
mg/dl, although a U-shaped relationship is observed between HDL-C and all-cause mortality. (J Am Coll Cardiol
2008;51:49–55) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.086t
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Ps noted by the National Cholesterol Education Program–
dult Treatment Panel III (NCEP-ATP III) guidelines,
ow high-density lipoprotein cholesterol (HDL-C) repre-
ents a key determinant of the Framingham risk score and a
See page 56
ommon critical risk factor for ischemic heart disease (IHD)
1). Low HDL-C levels, defined as below 40 mg/dl for men
nd 50 mg/dl for women, remain prevalent (1–3), and
umerous prospective cohort studies support a powerful
nverse correlation between circulating HDL-C levels and
oronary risk (4–11).
rom the *Department of Cardiology, Stanford University Hospital, Stanford,
alifornia; and the †Department of Cardiology, Veterans Administration Palo Alto
ealth Care System, Palo Alto, California.o
Manuscript received May 2, 2007; revised manuscript received July 23, 2007,
ccepted July 24, 2007.One significant limitation to those analyses, however, is
hat no study examined the clinical relevance of HDL-C
ithin the context of the optional aggressive low-density
ipoprotein cholesterol (LDL-C) target for higher-risk pa-
ients, below 70 mg/dl, as proposed by the 2004 update to
he NCEP-ATP III (12). As such, it remains unclear
hether very low LDL-C levels, now readily attainable with
otent statins and combination lipid-lowering therapy, at-
enuate or extinguish the cardiovascular risk associated with
ow HDL-C. We therefore sought to quantify the cardio-
ascular risk associated with low HDL-C among patients
ith LDL-C levels below 60 mg/dl, either occurring
pontaneously or achieved with lipid-lowering agents.
ethods
opulation cohort. We identified male patients seen at the
alo Alto Veterans Administration (VA) Medical Center or
ne of 7 affiliated community clinics with fasting LDL-C
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ber 1, 1999, and September 30,
2005. For patients with more
than 1 qualifying LDL-C value,
we used the earliest value to de-
termine the index date.
Comorbid conditions were de-
fined as present at baseline if the
relevant diagnostic code was re-
corded in any patient encounter
within 5 years before the index
date: IHD (International Classi-
fication of Diseases, Ninth Revi-
sion, Clinical Modification
[ICD-9-CM] 410 to 414), cere-
brovascular disease (ICD-9-CM
433 to 436), peripheral arterial
disease (ICD-9-CM 440 to
41), congestive heart failure (ICD-9-CM 428), diabetes
ellitus (ICD-9-CM 250), hypertension (ICD-9-CM 401
o 405), malignancy (ICD-9-CM 140 to 208), chronic
bstructive pulmonary disease (ICD-9-CM 490 to 496),
iver disease (ICD-9-CM 570 to 571), and alcohol depen-
ence or abuse (ICD-9-CM 303 or 305). Computerized
iagnostic coding at our institution has been demonstrated
o be accurate compared with chart review (13). The
ollowing laboratory abnormalities were defined as present
t baseline if recorded within 12 months before the index
ate: troponin I (TnI) 0.07 ng/ml, creatinine 2 mg/dl,
emoglobin 10 g/dl, aspartate aminotransferase 500
U/l, and hemoglobin A1c 7%. Use of statins, fibrates,
ngiotensin-converting enzyme inhibitors, angiotensin-
eceptor blockers, or beta-blockers was defined as a pre-
cription provided by the physician within 12 months before
he index date.
linical outcomes. We selected as the combined primary
nd point myocardial injury (defined as TnI 0.07 ng/ml)
r hospitalization with a primary diagnosis of IHD (ICD-
-CM 410 to 414) at 1 year. The secondary end point was
ll-cause mortality, with vital statistics obtained from the
A death records and the Social Security Death Index.
tatistical analysis. The patient cohort was divided into
uartiles (Q1 to Q4) based on HDL-C values measured on
he index date. Odds ratios for study outcomes were
alculated for each quartile using multivariate logistic re-
ression, adjusting for demographics (age, gender, race),
edical history (IHD, stroke, peripheral arterial disease,
eart failure, diabetes, hypertension, malignancy, chronic
bstructive pulmonary disease, liver disease, alcohol use or
ependence), laboratory values (LDL-C, triglycerides, TnI
0.07 ng/ml, creatinine 2 mg/dl, hemoglobin 10 g/dl,
spartate aminotransferase 500 IU/l, hemoglobin A1c
7%), and medication use (statins, fibrates, angiotensin-
onverting enzyme inhibitors, angiotensin-receptor blockers,
eta-blockers). Given the known association between levels of
Abbreviations
and Acronyms
HDL-C  high-density
lipoprotein cholesterol
ICD-9-CM  International
Classification of Diseases,
Ninth Revision, Clinical
Modification
IHD  ischemic heart
disease
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
OR  odds ratio
Q  quartile
TnI  troponin Iriglycerides and HDL-C values, the square of the triglycer- ydes was added as a covariate to improve risk adjustment in
ultivariable analyses. Pearson chi-square analysis was used
o evaluate categoric variables and analysis of variance to
valuate continuous variables. Based on earlier studies sug-
esting a U-shaped relationship between HDL-C and total
ortality, we tested the hypothesis that adjusted odds ratios
ORs) for 1-year mortality were similar for HDL-C values
bove and below the midpoint of Q3 (43 mg/dl). A p value
f 0.05 was considered to be statistically significant.
tatistical analyses were performed using Stata version 9.0
StataCorp, College Station, Texas). All of the authors had
ull access to the data and take responsibility for its integrity.
ll of the authors read and agreed to the manuscript as
ritten.
esults
aseline characteristics. Characteristics of the cohort, cat-
gorized according to HDL-C quartile, are shown in Table 1.
total of 4,118 consecutive patients met inclusion criteria with
n LDL-C below 60 mg/dl, of which 2,254 (54%) had an
DL-C below 40 mg/dl. Mean quartile HDL-C values were:
1 28 mg/dl, Q2 36 mg/dl, Q3 43 mg/dl, and Q4 63
g/dl. Mean LDL-C values by quartile were: Q1 47 mg/dl,
2 49 mg/dl, Q3 50 mg/dl, and Q4 50 mg/dl. A history of
HD was noted in 35% to 46% of the cohort. Individuals in
he lower HDL-C categories tended to have: higher rates of
HD, stroke, peripheral arterial disease, heart failure, dia-
etes, and prior myocardial injury; abnormal levels of
reatinine, hemoglobin, hemoglobin A1c, and triglycerides;
nd greater use of fibrates, angiotensin-converting enzyme
nhibitors or angiotensin-receptor blockers, and beta-
lockers. Chronic obstructive pulmonary disease and alco-
ol dependence or abuse were more likely to be observed in
he higher HDL-C quartiles.
DL-C quartile and risk of coronary events. At 1 year,
15 patients suffered myocardial injury, 104 patients re-
uired hospital admission for IHD, and 535 patients expe-
ienced either myocardial injury or IHD hospitalization.
nivariate analysis demonstrated an inverse relationship
etween HDL-C and the combined primary end point of
yocardial injury or IHD hospitalization at 1 year (Q1
7.0%, Q2 12.7%, Q3 13.1%, Q4 10.9%; p  0.001)
Fig. 1). The above-average absolute incidence of coronary
vents may be explained by the prevalence of IHD in the
ohort at baseline. In multivariate-adjusted analysis, the
Rs for myocardial injury or IHD admission at 1 year
aried inversely to HDL-C quartile (ORs: Q1 1.59 [95%
onfidence interval (CI) 1.16 to 2.19], Q2 1.39 [95% CI
.01 to 1.92], Q3 1.33 [95% CI 0.96 to 1.84], and Q4
eference) (Fig. 2). Analyzing HDL-C as a continuous
ariable revealed a 10% increase (95% CI 3% to 17%) in the
ombined primary end point of myocardial injury or IHD
dmission for every 10-mg/dl decrease in HDL-C. Sub-
roups revealed findings consistent with the primary anal-
sis (Table 2). None of the interactions between the
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cant (all p  0.2). Of note, the univariate relationship
etween the ratio total cholesterol/HDL-C and out-
omes was not statistically significant (Q1 13.9%, Q2
3.8%, Q3 13.5%, Q4 12.5%; p  0.80).
DL-C quartile and risk of total mortality. In univariate
nalysis, a U-shaped relationship was observed between
DL-C and the risk of overall mortality at 1 year (Q1
.2%, Q2 6.5%, Q3 6.3%, Q4 9.2%; p  0.011) (Fig. 1).
his relationship persisted in multivariable analysis adjusted
or demographics, medical history, laboratory values, and
edication use (Fig. 2). Analysis of the ORs for death from
ny cause using the highest HDL-C quartile as the refer-
nce quartile revealed a U-shaped curve, with the highest
isk of mortality observed in the lowest and highest quartiles
ORs: Q1 1.13 [95% CI 0.79 to 1.62], Q2 0.97 [95% CI
ackground Characteristics by HDL-C Quartile
Table 1 Background Characteristics by HDL-C Quartile
Characteristic
Q1 (n  1,082)
Mean 28 mg/dl
Q2
Me
Demographics
Age (yrs) 64
Race
White 48%
Black 3%
Hispanic 7%
Asian 2%
Unknown 40%
Medical history
IHD 45%
Stroke 12%
Peripheral arterial disease 6%
Heart failure 22%
Diabetes 53%
Hypertension 75%
Malignancy 20%
Chronic obstructive pulmonary disease 29%
Liver disease 5%
Alcohol abuse or dependence 14%
Laboratory values
Mean LDL-C (mg/dl) 47
Mean TG (mg/dl) 209
TnI 0.07 ng/ml 18%
Cr 2 mg/dl* 27%
Hb 10 g/dl* 16%
AST 500 IU/l* 4%
HbA1c 7%* 51%
Medication use
Statin 49%
Fibrate 12%
ACEI or ARB 56%
Beta-blocker 42%
Laboratory abnormalities were recorded within 12 months before the index low-density lipoprotei
b (n  3,667), AST (n  4,019), HbA1c (n  2,358).
ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin-receptor blocker; AST asp
HD  ischemic heart disease; Q  quartile; TG  triglycerides..67 to 1.40], Q3 0.74 [95% CI 0.50 to 1.09], and Q4 reference), similar to findings observed in prior epidemio-
ogic studies (Fig. 3) (14–17). The ORs for total mortality
or every HDL increase of 10 mg/dl was 1.09 [95% CI 0.98
o 1.20] if the HDL was above 43 mg/dl and 0.73 [95% CI
.60 to 0.88] if the HDL was below 43 mg/dl; for difference
n ORs: p  0.001. If alcohol abuse or dependence was
emoved from the model, the OR for all-cause mortality in
he lowest HDL-C quartile decreased compared with the
ighest HDL-C quartile (adjusted for alcohol: 1.13 [95%
I 0.79 to 1.62]; not adjusted for alcohol: 0.88 [95% CI
.62 to 1.24]), suggesting the role of alcohol use as a
omponent of the observed worsened outcomes.
iscussion
s noted by the NCEP-ATP III guidelines, low HDL-C
HDL-C by Quartile
1,123)
mg/dl
Q3 (n  939)
Mean 43 mg/dl
Q4 (n  1,044)
Mean 63 mg/dl p Value
67 65 0.001
0.001
% 45% 45%
% 5% 9%
% 6% 5%
% 3% 2%
% 41% 39%
% 46% 35% 0.001
% 12% 9% 0.185
% 4% 3% 0.014
% 16% 12% 0.001
% 45% 35% 0.001
% 75% 67% 0.001
% 23% 18% 0.081
% 27% 32% 0.001
% 4% 6% 0.012
% 11% 26% 0.001
50 50 0.001
177 116 0.001
% 12% 10% 0.001
% 24% 16% 0.001
% 10% 10% 0.001
% 3% 5% 0.007
% 48% 42% 0.002
% 63% 44% 0.001
% 7% 3% 0.001
% 51% 41% 0.001
% 40% 25% 0.001
sterol (LDL-C) date. Numbers indicate percent of patients tested for the following: Cr (n  4,074),
minotransferase; Cr creatinine; Hb hemoglobin; HDL-C high-density-lipoprotein cholesterol;(n 
an 36
66
45
4
7
3
42
46
12
4
17
52
78
19
24
4
11
49
203
13
22
9
2
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9
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42
n choleepresents a key determinant of the Framingham risk score
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Significance of HDL-C in Patients With Low LDL-C January 1/8, 2008:49–55nd a common critical risk factor for IHD (1). Isolated low
DL-C was the most frequent dyslipidemia observed in a
tudy of men with angiographically documented premature
HD (18). A survey of 8,650 male veterans with IHD
evealed an HDL-C of 40 mg/dl in 63% of the study
ohort (3). In a large study of 8,545 cardiology patients in 11
uropean countries, HDL-C 40 mg/dl occurred in 33%
f men and 40% of women despite lipid-lowering therapy
nd lifestyle modification (2). Approximately 45% of pa-
ients had a diagnosis of IHD, and 85% received statin
herapy, achieving a mean LDL-C of 118 mg/dl. Finally,
ccording to 2007 American Heart Association heart dis-
ase statistics, 25% of men aged 20 years and older have
DL-C values of 40 mg/dl (19).
Numerous prospective cohort studies support a powerful
nverse correlation between circulating HDL-C and coro-
ary risk among patients with normal or elevated LDL-C
4,20). According to the Framingham Heart Study, among
atients aged 50 to 80 years without IHD, after a mean
ollow-up of 4 years, the risk of MI or IHD death decreased
y 25% for every 10-mg/dl increase in HDL-C (6). After 21
ears of observation, the Israeli Ischemic Heart Disease
tudy of men without IHD at baseline demonstrated an
ncreased risk of IHD mortality (adjusted risk ratio 1.22 to
.25) among subjects with HDL-C35 mg/dl regardless of
otal cholesterol levels (21). In the Pravastatin Pooling
roject, among IHD patients with LDL-C125 mg/dl not
n statin therapy, a 10-mg/dl increase in HDL-C was
ssociated with a 29% decrease in the combined end point of
HD death, nonfatal myocardial infarction, or coronary
evascularization after a mean follow-up of 5 years (10).
ore recently, low HDL-C was shown to be a key
Figure 1 Unadjusted Rates of the
Combined Primary End Point
Unadjusted rates of myocardial injury or ischemic heart disease (IHD) hospital-
ization (n  3,982) and the secondary end point, all-cause mortality (n 
4,188), at 1 year after the index low-density lipoprotein cholesterol date are
shown. In univariate analysis, an inverse relationship was shown between high-
density lipoprotein cholesterol (HDL-C) and admission for IHD, whereas a
U-shaped relationship was observed between HDL-C and the risk of overall
mortality at 1 year. p  0.001 for myocardial injury or IHD hospitalization; p 
0.01 for total mortality. Q1 to Q4  HDL-C quartiles 1 to 4.redictor of major adverse cardiac events and death (hazardatio 2.6 to 3.3) after percutaneous coronary intervention for
cute coronary syndrome (22).
Several randomized controlled trials of antidyslipidemic
herapies suggest that raising HDL-C may be associated
ith decreased cardiovascular risk (20). The Helsinki Heart
tudy examined the effect of gemfibrozil on lipid parameters
nd cardiovascular outcomes among men without IHD and
ith primary dyslipidemia, defined as non–HDL-C 200
g/dl (23). After 5 years of follow-up, treatment with
emfibrozil increased HDL-C by 11%, decreased LDL-C
nd triglycerides by 11% and 35%, respectively, and reduced
he incidence of MI and IHD death by 34% compared with
lacebo. Subsequent analysis estimated that the significant
eduction in IHD risk associated with a 1% increment in
DL-C (3%) exceeded that achieved with an equivalent
agnitude decrement in LDL-C (2%) or triglycerides
0%) (24). Findings from the VA-HIT (VA HDL Inter-
ention Trial) demonstrated that a 6% increase in HDL-C,
chieved with the use of gemfibrozil, decreased IHD death
nd nonfatal MI by 22% after 5 years of therapy among
HD patients with an HDL-C of 40 mg/dl (mean 32
g/dl) (7,8). Treatment with niacin has been associated
ith increased HDL-C and decreased mortality, as well.
efore the advent of statins, the Coronary Drug Project
howed that niacin therapy in men with IHD reduced the
isk of MI by 26%, stroke by 24%, and the need for coronary
evascularization by 67% compared with placebo after a
ean 6.5 years of follow-up (25). Post-trial analysis con-
ucted 9 years after treatment discontinuation revealed an
Figure 2 Adjusted Odds Ratios for
the Combined Primary End Point
Adjusted odds ratios of myocardial injury or ischemic heart disease (IHD)
admission (n  3,884) and the secondary end point, death from any cause
(n  4,070), at 1 year after the index low-density lipoprotein cholesterol date
are shown. In multivariate-adjusted analysis using the highest high-density
lipoprotein cholesterol (HDL-C) quartile (Q4) as the reference quartile, an
inverse relationship was shown between HDL-C and admission for IHD,
whereas a U-shaped relationship was observed between HDL-C and the risk of
overall mortality at 1 year. The p values for myocardial injury or IHD admission:
0.04 HDL-C categoric, 0.007 HDL-C continuous. The p values for total mortal-
ity: 0.18 HDL-C categoric, 0.001 for separate linear relationships above and
below HDL-C of 43 mg/dl.
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he HATS (HDL-Atherosclerosis Treatment Study) trial,
ombination niacin-simvastatin therapy administered to
Adjusted Odds Ratios for the Combined PrimaryInjury, or Ischemic Heart Disease Admission t
Table 2 Adjusted Odds Ratios for the CombInjury, or Ischemic Heart Disease A
Subgroup n
Ischemic heart disease
No history 2,192
History 1,692
Recent myocardial injury*
None within prior year 3,383
Within prior year 501
Diabetes mellitus
No history 2,056
History 1,828
Comorbid disease†
No history 2,294
History 1,590
Statin use
No use at baseline 1,756
Use at baseline 2,128
*Recent myocardial injury is defined as a documented troponin I of0
failure, malignancy, liver disease, renal disease, or anemia.
CI  confidence interval; OR  odds ratio; other abbreviations as in
Figure 3 Risk Ratios for Death From Any Cause
In multivariable analysis adjusted for demographics, medical history, laboratory
values, and medication use, analysis of the odds ratios for death from any
cause using the highest high-density lipoprotein cholesterol (HDL-C) quartile
(Q4) as the reference quartile revealed a U-shaped curve, with the highest risk
of mortality observed in the lowest and highest quartiles, similar to findings
observed in earlier epidemiologic studies. *Adjusted for age, diastolic blood
pressure, and cigarettes/day. †Not adjusted. ‡Adjusted for age, mean daily
alcohol consumption, body mass index, education, physical activity, cigarettes/
day, systolic blood pressure, and total cholesterol. §Adjusted for age.
Adjusted for age, gender, ischemic heart disease, stroke, peripheral arterial
disease, congestive heart failure, diabetes, hypertension, malignancy, chronic
obstructive pulmonary disease, liver disease, alcohol dependence or abuse,
statin use, fibrate use, creatinine, hemoglobin A1c, troponin, hemoglobin, low-
density lipoprotein cholesterol, aspartate aminotransferase, and triglycerides.
PAVA  Palo Alto Veterans Administration (present study). Q1 to Q4  HDL-C
quartiles 1 to 4; Q1 to Q5  HDL-C quintiles 1 to 5; S1 to S6  HDL-C sex-
tiles 1 to 6; T1 to T3  HDL-C tertiles 1 to 3.aHD patients with low HDL-C was associated with a 26%
ncrease in HDL-C compared with placebo, a 60% to 90%
eduction in death, myocardial infarction, stroke, or revas-
ularization, and plaque regression by serial angiography (5).
n comparison, multiple trials of statins alone achieved event
eduction of only 24% to 34% and slowed but did not
everse atheroma progression (5). The most recent trial of
DL-directed therapy, the ARBITER (Arterial Biology
or the Investigation of the Treatment Effects of Reducing
holesterol)-2 study, examined the effects of niacin added
o background statin therapy on HDL-C and carotid
ntima-media thickness (CIMT), a validated surrogate car-
iovascular end point (13). After 12 months of therapy,
xtended-release niacin increased HDL-C by 21% and
ecreased the rate of CIMT progression. Mean CIMT was
nchanged in the niacin group compared with baseline
0.014 mm; p  0.026) and increased significantly in the
lacebo group (0.044 mm; p  0.001). Per-protocol
nalysis at 24 months suggested a significant regression of
IMT among niacin-treated patients compared with the
lacebo arm (0.041 mm; p  0.001) (10). After control-
ing for changes in LDL-C and triglycerides, only differ-
nces in HDL-C were independently associated with
IMT regression. These consistent findings highlight both
he prevalence and risk associated with low HDL-C and
uggest that improved clinical outcomes may accompany
ncreases in HDL-C.
The present study extends the clinical importance of
irculating HDL-C levels to patients with very low LDL-C
evels, defined as 60 mg/dl, and confirms the high
revalence of the at-risk HDL-C profile. Every 10-mg/dl
ecrease in HDL-C was associated with a 10% increase in
he combined end point of myocardial injury or IHD
Point, Myocardialr, According to Subgroups
Primary End Point, Myocardial
sion at 1 Year, According to Subgroups
5% CI) of Myocardial Injury or IHD
ssion per 10-mg/dl HDL-C Increase p Value
0.92 (0.84–1.02) 0.13
0.88 (0.78–0.99) 0.04
0.91 (0.83–1.00) 0.04
0.93 (0.80–1.08) 0.36
0.91 (0.82–1.01) 0.07
0.88 (0.78–1.01) 0.06
0.87 (0.77–0.97) 0.02
0.87 (0.79–0.97) 0.008
0.90 (0.82–1.00) 0.04
0.89 (0.79–1.01) 0.07
l within the preceding 1 year. †Comorbid disease includes prior heart
1.End1 Yea
ined
dmis
OR (9
Admi
.7 ng/mdmission at 1 year. Subgroup analysis of patients on statin
t
a
t
w
o
m
l
a
n
r
L
A
l
f
v
c
C
H
n
m
c
H
d
i
o
u
i
o
q
U
U
r
w
a
c
a
f
m
s
m
d
p
i
H
t
o
f
r
c
q
L
E
a
l
(
s
p
u
t
p
I
e
g
p
c
e
t
t
S
p
s
h
V
n
n
c
a
H
n
l
e
s
i
p
I
t
p
i
e
L
a
H
t
e
p
u
w
c
s
s
H
R
3
m
C
54 deGoma et al. JACC Vol. 51, No. 1, 2008
Significance of HDL-C in Patients With Low LDL-C January 1/8, 2008:49–55herapy revealed a similar effect on the combined end point
mong the lowest 3 HDL-C quartiles, suggesting perhaps
hat statin use may attenuate the increased risk associated
ith low HDL-C.
Importantly, the inverse correlation between spontane-
usly occurring HDL-C values and cardiovascular outcomes
ay not be reliable in the setting of genetic or pharmaco-
ogic manipulation, despite the observations of the VA-HIT
nd HATS trials. Raising HDL-C, in other words, need
ot confer an atheroprotective benefit, as illustrated by the
ecent termination of the ILLUMINATE (Investigation of
ipid Level Management to Understand Its Impact in
therosclerotic Events) trial. Despite increasing HDL-C
evels by 72%, administration of the cholesteryl ester trans-
er protein inhibitor torcetrapib in combination with ator-
astatin was associated with a higher risk of mortality
ompared with atorvastatin alone (hazard ratio 1.58; 95%
I 1.14 to 2.19; p  0.006) (27). The potential benefit of
DL-directed drugs in development, as well as the prog-
ostic utility of HDL-C as a surrogate marker after phar-
acotherapy, awaits the results of ongoing trials with “hard”
linical end points. Until then, directly addressing low
DL-C relies largely upon niacin administration and car-
iac rehabilitation, which have been demonstrated to both
ncrease HDL-C (30% and 11%, respectively) and improve
utcomes (28,29).
In the present study, the risk of death from any cause,
nlike IHD-related outcomes, did not fit a monotonic
nverse correlation with HDL-C. Worsened outcomes were
bserved in not only the lowest but also the highest HDL-C
uartile. Earlier epidemiologic studies conducted in the
.S., Norway, Finland, and Russia revealed a similar
-shaped relationship (Fig. 3) (14–17,30). The IHD-
elated mortality in those analyses consistently decreased
ith higher HDL-C values; however, deaths attributed to
lcohol, violence, or accidents rose continuously with in-
reasing HDL-C. One plausible hypothesis holds that,
lthough atheroprotective, HDL-C also represents a marker
or noncardiovascular conditions associated with significant
orbidity and mortality, such as alcohol use. Of note, in a
tudy of 1,962 Russian men, levels of apolipoprotein AI, the
ajor apolipoprotein component of HDL, paralleled the
egree of alcohol use across various age groups (31). In the
resent study, adjustment for alcohol abuse or dependence
ncreased the OR for death from any cause in the lowest
DL-C quartile compared with the reference, supporting
he role of increased alcohol use as a component of the
bserved worsened outcomes. Adjustment failed to account
or all of the excess risk, suggesting that either under-
eporting of alcohol use or unknown confounding factors
ontributed to increased mortality in the highest HDL-C
uartile.
The strengths of the present study include the stringent
DL-C inclusion criteria and the large study cohort.
ligibility required an LDL-C of 60 mg/dl, limitingnalyses to patients not previously examined in epidemio-ogic studies or clinical trials. A recent analysis of the TNT
Treating to New Targets) study found an inverse relation-
hip between HDL-C and cardiovascular events among
atients with LDL-C80 mg/dl (32). The present study is
nique in that its LDL-C threshold of 60 mg/dl lies below
he optional aggressive 70 mg/dl target for higher-risk
atients proposed by the 2004 update to the NCEP-ATP
II (12). The present findings therefore demonstrate that
ven among patients with LDL-C levels well below current
uidelines, either occurring spontaneously or achieved with
harmacotherapy, low HDL-C carries prognostic signifi-
ance. In addition, this study evaluated a diverse population
ncompassing both primary and tertiary care centers,
hereby permitting generalizability of its findings beyond
he clinical trial setting.
tudy limitations. Despite our attempts to control for
otential confounders, the nonexperimental design remains
usceptible to bias; consequently, unmeasured variables may
ave confounded results. Our study used a database from a
A health care system covering much of northern Califor-
ia. As such, the patients were predominately male, and
onfatal events that occurred outside the system were not
aptured. However, the number of observed events was
dequate to demonstrate a significant association between
DL-C and outcomes. Furthermore, it is unlikely that
oncaptured events were systematically more or less preva-
ent among those with low HDL-C. Finally, we did not
xamine other lipoprotein parameters such as LDL particle
ize, apolipoprotein B, and lipoprotein (a), and, without
nformation regarding cause of death, we were unable to
rovide data regarding cardiovascular or cancer mortality.
mplications for clinical practice. Management of pa-
ients presenting with a combined low HDL-low LDL lipid
rofile remains a clinical conundrum, one likely to become
ncreasingly prevalent with the availability of safe and
ffective LDL-lowering strategies. In the setting of low
DL-C, no evidence has been available to support or refute
dditional cardiovascular risk conferred by decreased
DL-C. The present study provides such evidence, iden-
ifying an inverse relationship between HDL-C and IHD
vents even among patients with LDL-C 60 mg/dl that
ersisted after adjustment for patient comorbidities. It is
nclear if statin use attenuates the increased risk associated
ith low HDL-C. These findings support the need for
omprehensive risk assessment, including HDL-C mea-
urement, for all patients regardless of LDL-C status and
uggest vigilant risk factor modification among the low
DL population.
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